一种可解释的机器学习方法用于阿尔茨海默氏症疾病分类.
Abbas Saad Alatrany1,2,3,4, Wasiq Khan5, Abir Hussain6,7
1School of Computer Science and Mathematics, Liverpool John Moores University, Liverpool, UK. a.s.alatrany@2020.ljmu.ac.uk.
Scientific reports
|February 1, 2024
概括
机器学习模型使用国家阿尔茨海默氏症协调中心数据准确预测阿尔茨海默氏症 (AD) 风险和进展. 可解释的AI方法识别了诸如记忆和判断等关键因素,有助于早期诊断和了解AD发展.
科学领域:
- 神经学 神经学
- 计算生物学 计算生物学
- 生物统计学 生物统计学
背景情况:
- 由于微妙的生物标志物变化,早期阿尔茨海默病 (AD) 诊断具有挑战性.
- 机器学习 (ML) 提供了识别AD风险的潜力,但往往缺乏解释性.
- 高维度和有限的数据集在AD研究中带来了挑战.
研究的目的:
- 开发和验证可解释的ML模型,用于早期AD诊断和进展预测.
- 通过可解释的ML方法识别导致AD发展的关键因素.
- 为了利用大规模的数据集进行强大的AD风险评估.
主要方法:
- 使用国家阿尔茨海默氏症协调中心数据集 (169,408条记录,1024个特征) 减少了特征空间.
- 训练支持向量机 (SVM) 模型用于二进制 (NC与NC对比) 的模型. AD) 和多类分类和进展预测.
- 采用规则提取技术 (类规则挖掘,稳定和可解释的规则集) 和SHAP/LIME用于模型解释性.
主要成果:
- SVM模型实现了高性能:98.9%的F1分数用于二进制分类和90.7%的多类分类.
- SVM准确地预测了AD的进展 (88%F1对于二进制,72.8%对于多类).
- 可解释的人工智能确定了关键因素:记忆,判断,共同点,方向和临床痴呆症评级工具.
结论:
- 可解释的ML模型在AD诊断和进展预测方面表现出高准确度.
- 确定了关键的认知和临床因素,对于理解AD发展至关重要.
- 该研究强调了可解释的ML在阿尔茨海默病临床决策支持中的有用性.
更多相关视频
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.5K
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
相关概念视频
Alzheimer's Disease: Overview
487
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
487
Alzheimer's Disease: Treatment
193
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
193
